Celecoxib-Induced Cholestatic Hepatotoxicity in a Patient with Cirrhosis
Authors: Paulo Alegria, Luís Lebre, Cristina Chagas
Journal: Annals of Internal Medicine (2002)

Letters2 July 2002Celecoxib-Induced Cholestatic Hepatotoxicity in a Patient with CirrhosisPaulo Alegria, MD, Luís Lebre, MD, and Cristina Chagas, MDPaulo Alegria, MDHospital de Santa Cruz; Carnaxide, Portugal (Alegria, Lebre, Chagas), Luís Lebre, MDHospital de Santa Cruz; Carnaxide, Portugal (Alegria, Lebre, Chagas), and Cristina Chagas, MDHospital de Santa Cruz; Carnaxide, Portugal (Alegria, Lebre, Chagas)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-1-200207020-00030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A 49-year-old man with alcoholic cirrhosis of the liver developed jaundice, fatigue, and choluria after he began taking celecoxib, 200 mg/d, for minor musculoskeletal pain. He took the drug for 15 days before presentation. The patient had a history of heavy alcohol consumption and had developed ascites 6 months earlier. At that time, chronic hepatic disease had been diagnosed, and viral serologic characteristics compatible with previous contact with hepatitis B virus had been detected. The patient had received althiazide, spironolactone, oxazepam, tiapride, lactitol, vitamins, and minerals and remained clinically well (anicteric, with no ascites or edema) during ...References1. Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic hepatitis [Letter]. Ann Intern Med. 2001;134:254. [PMID: 11177350] LinkGoogle Scholar2. Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis: a case report. Arch Intern Med. 2000;160:553-4. [PMID: 10695699] CrossrefMedlineGoogle Scholar3. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225-42. [PMID: 10749518] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Hospital de Santa Cruz; Carnaxide, Portugal (Alegria, Lebre, Chagas) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCelecoxib-Induced Cholestatic Hepatitis Mark V. Galan , Stuart C. Gordon , and Ann L. Silverman Metrics Cited ByLiver Injury Induced by the Interaction Between Fluoxetine and Celecoxib: A Case Report and the Literature ReviewA case of acute liver failure induced by Pregabalin and CelecoxibCelecoxib-induced Liver InjuryHepatotoxicity induced by coxibs: how concerned should we be?Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondriaCelecoxibClinical implications of prescribing nonsteroidal anti-inflammatory drugs in oral health care—a reviewA case of drug-induced liver injury by celecoxibDrug-Induced Liver DiseaseComparative Adverse Effects Of Cox-1 and Cox-2 Inhibitors in Rat Liver: An Experimental Study."NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trialsLate-onset celecoxib-induced combined hepato-nephrotoxicityIdiosyncratic drug-induced liver injury: an overviewHepatic ToxicologyHepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reportsNon-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systemsCelecoxibProlonged cholestasis associated with short-term use of celecoxibEffects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascitesSulfonamide Cross-Reactivity: Fact or Fiction?Management of hepatitis C virus-related arthritisAdverse hepatic drug reactions: inflammatory episodes as consequence and contributorSafety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring studyHepatocellular damage from non-steroidal anti-inflammatory drugsHepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?Cholestatic syndromesCurrent Awareness: Pharmacoepidemiology and Drug SafetyAnti-inflammatory and antipyretic analgesics and drugs used in gout 2 July 2002Volume 137, Issue 1Page: 75KeywordsAlcohol consumptionAscitesBilirubinCirrhosisSafetySafety studiesSerum glutamic oxaloacetic transaminaseSteatosisViral diseasesVitamins ePublished: 2 July 2002 Issue Published: 2 July 2002 CopyrightCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...